Nintedanib
Back to searchMolecule Structure
Scientific Name
Nintedanib
Description of the Drug
Nintedanib is a triple angiokinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and in combination with docetaxel for non-small cell lung cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09079
http://www.drugbank.ca/drugs/DB09079
Brand Name(s)
Ofev, Vargatef
Company Owner(s)
Boehringer Ingelheim Pharmaceuticals Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Fibroblast growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2095217 |
Platelet-derived growth factor receptor | PROTEIN COMPLEX | INHIBITOR | CHEMBL2095189 |
Vascular endothelial growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2095227 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL431006 | ||
DrugBank | DB09079 | ||
PubChem: Thomson Pharma | 14836969 | ||
Nikkaji | J2.815.614F | ||
PDBe | XIN | ||
BindingDB | 50026612 | ||
DrugCentral | 4903 | ||
Brenda | 247462 | ||
ChemicalBook | CB72510401 | CB92467147 | CB92469909 |
Guide to Pharmacology | 5936 | ||
rxnorm | OFEV | NINTEDANIB ESYLATE | NINTEDANIB |
PubChem: Drugs of the Future | 99431587 | ||
ChEBI | 85164 | ||
ZINC | ZINC000100014909 |